Admin_Adham
A recent phase 3 study of more than 800 adults, published in Nature, revealed encouraging results for a cannabis extract in treating chronic low back pain, offering new hope for patients seeking nonopioid relief.
VER-01, a full-spectrum Cannabis sativa extract, provided sustained pain reduction while also improving sleep quality and physical function, and without requiring dose escalation.
The results of this study are of particular interest given the limitations of current treatments: NSAIDs offer modest relief with long-term gastrointestinal, cardiovascular, and kidney risks, while opioids can reduce pain but carry a high risk for addiction.
The treatment showed significant pain reduction compared to placebo, with the benefit being greater in patients with neuropathic pain.
In the 6-month extension, nearly three quarters of participants achieved at least a 30% reduction in pain, and more than half reached a 50% reduction.
While adverse effects were reported during titration, especially dizziness, drowsiness, and nausea, they were typically mild to moderate and temporary. Of note, researchers found no evidence of dependence or withdrawal symptoms.
This study stands out for its rigorous design, including its double-blind, placebo-controlled methodology and adequate treatment duration, offering a potential treatment option for chronic back pain management.
This content was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
